Le Lézard
Classified in: Health, Business
Subjects: SVY, LEG, POL

Uncertainty Returns to Healthcare Industry Out-of-Court Restructurings with Senate Rejecting ACA Repeal


NEW YORK, Aug. 15, 2017 /PRNewswire/ -- Uncertainty with the Affordable Care Act and rising costs will prompt more out-of-court restructurings in the healthcare industry, while the retail and energy sectors will have a steady flow of restructurings through the end of the year, according to restructuring attorneys and advisers, according to The Deal, a business unit of TheStreet, Inc. (NASDAQ: TST). 

The Deal. (PRNewsFoto/The Deal Pipeline)

"Healthcare industry out-of-court restructurings seemed to return to stability in the second quarter of 2017 based on assumptions by restructuring advisers that the Affordable Care Act was on firm ground," said Kirk O'Neil, out-of-court restructuring reporter at The Deal. "But uncertainty in the healthcare industry has returned for the second half of 2017, as President Trump continues his campaign to undermine the ACA after the U.S. Senate rejected legislation to repeal the act."

The report also mentions the healthcare, retail and energy sectors will be the most active for out-of-court restructurings through the end of 2017.

The Deal's exclusive ranking covers the top global advisers involved in out-of-court cases filed between January 1 and June 30, 2017.

Some highlights from the report:

The full article is available online, or learn more about The Deal's Out-of-Court League Tables by visiting http://www.thedeal.com/out-of-court/.

About The Deal's Out-of-Court Restructuring League Tables
The Deal's Out-of-Court Restructuring league tables are based on distressed companies experiencing financial restructuring ongoing or completed during the period under review. Minimum requirements for inclusion include: announcement, completion or reference date; at least one (1) instrument of debt amount stated (bond, note, loan, credit facility, etc.); credit facility security (secured or unsecured); and name of the distressed company. Roles in the league tables will be: legal advisory, financial advisory and other advisory (including Public Relations or Restructuring Adviser). There are neither geographic nor company value size restrictions for the distressed company.

About The Deal 
The Deal (www.thedeal.com) provides actionable, intraday coverage of mergers, acquisitions and all other changes in corporate control to institutional investors, private equity, hedge funds and the firms that serve them. The Deal is a business unit of TheStreet, Inc. (NASDAQ: TST, www.t.st), a leading financial news and information provider. Other business units include TheStreet (www.thestreet.com), an unbiased source of business news and market analysis for investors; BoardEx ( www.boardex.com), a relationship mapping service of corporate directors and officers; and RateWatch (www.rate-watch.com), which supplies rate and fee data from banks and credit unions across the U.S.

Contact: Jon Kostakopoulos, 212-321-5561, Jon.Kostakopoulos at thestreet.com

 

SOURCE TheStreet, Inc.


These press releases may also interest you

at 04:00
Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to the global clinical trials industry, today announced the launch of SUBMIT24 in its beta version during Q3 2024,...

at 04:00
TVM Capital Healthcare, a specialist healthcare private equity firm headquartered in Dubai and...

at 03:26
Calliditas Therapeutics AB , ("Calliditas") today announced that the global open-label extension (OLE) study to the Phase 3 NefIgArd study showed a treatment response consistent with the NefIgArd study across endpoints of urine protein to creatinine...

at 03:00
Flindr...

at 03:00
CSL Vifor and Travere Therapeutics, Inc., today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the...

at 03:00
Tetra Pharm Technologies and Glysious are pleased to announce a strategic collaboration aimed at developing a ground-breaking transdermal drug delivery system complementing several of Tetra Pharm Technologies' pipeline candidates. The...



News published on and distributed by: